Allogene Therapeutics Appoints Zachary Roberts as President and CEO

On May 28, 2026, Allogene Therapeutics announced that its Board of Directors has appointed Zachary Roberts, M.D., Ph.D., as the Company’s new President and Chief Executive Officer, effective July 1, 2026. Dr. Roberts, who currently serves as Executive Vice President of Research and Development and Chief Medical Officer, will succeed David Chang, M.D., Ph.D. Dr. Chang will step down from his executive roles on June 30, 2026, but will remain on the Board as a non-employee director. Dr. Roberts has also been appointed as a Class I director with a term expiring in 2028. In connection with his promotion, Dr. Roberts will receive an annual base salary of $680,000 and a target annual bonus of 60%. His equity compensation includes an option to purchase 476,190 shares and a restricted stock unit (RSU) award for 134,530 shares, both subject to multi-year vesting schedules. Dr. Roberts brings extensive experience from previous leadership roles at Instil Bio, Kite, and Amgen. He will continue to serve as the Company's Chief Medical Officer on an interim basis.